What are the ways to deal with the side effects of Niraparib Abiraterone Tablets?

Niraparib Abiraterone Tablets (Akeega) has shown high efficacy and personalized treatment advantages in clinical treatment, but it also has a certain degree of adverse reactions. Patients should pay special attention to the prevention and management of side effects during use to ensure the safety and compliance of long-term medication. Common side effects are mainly caused by two components - the PARP inhibitor niraparib-related toxicities include fatigue, thrombocytopenia, anemia, nausea, insomnia, etc.; while abiraterone may cause hypertension, hypokalemia, abnormal liver function, and water and sodium retention.

In view of the hematopoietic system side effectsassociated with PARP inhibitors, it is recommended to check the complete blood count (CBC) regularly before, during and after medication. If a significant decrease in platelets or white blood cells is found, temporary drug discontinuation, dose reduction, or the use of white blood- and platelet-raising drugs for supportive treatment may be considered. Some patients will experience significant fatigue in the early stages of medication, which may be related to hematopoietic system suppression or metabolic stress, which can be alleviated through nutritional support, proper rest, and improved sleep quality.

As for the hormone-related side effects that abiraterone may induce, doctors usually routinely combine it with prednisone to suppress electrolyte imbalance caused by abnormal activity of the adrenal axis. Combined use with prednisone can help reduce the incidence of hypertension, edema, and hypokalemia. Electrolyte monitoring is the key to preventing risks. It is recommended that patients monitor blood potassium and blood pressure changes every 2 to 4 weeks. If abnormalities occur, potassium supplements, diet adjustments, or antihypertensive drugs should be added in time.

Abnormal liver function is also a problem that cannot be ignored, especially for patients taking abiraterone for a long time. It is recommended to regularly monitor ALT, AST, bilirubin and other indicators before treatment and every month during treatment. If there is a significant increase, the medication needs to be suspended and evaluated whether it can be resumed.

Reference materials:https://www.drugs.com/akeega.html